Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

51.34 +0.67 (+1.32%)
Official Closing Price Updated: 7:00 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
EXCLUSIVE: Be The House Not The Gambler — How To Use Options To Improve Performance
While investment results in the markets are not guaranteed, there are relatively simple options strategies that can greatly reduce risk and generate far more predictable returns in the long run. 
Via Benzinga
FDA Gives Green Signal To Pfizer/BioNTech's COVID-19 Booster For Kids 5-11 Years
 
Via Benzinga
FDA Declines Emergency Use Request For An Antidepressant As COVID-19 Treatment
 
Via Benzinga
Awardees named for $20 million project to foster diversity in clinical trial research
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Pfizer Retakes A Key Line — And Drags BioNTech, Moderna With It
The FDA decision also prodded BioNTech and Moderna stocks higher. 
Via Investor's Business Daily
Price Of Pfizer's Paxlovid Generic Version Capped At $25 Or Less For Low-Income Countries
 
Via Benzinga
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach... 
Via iCrowdNewswire
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Tuesday, May 17
Reuters KKR To Scoop This Power Company At 36% Premium 
Via Benzinga
FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT
 
Via Benzinga
Inflation May Have Peaked: What to Do Now
Last week was another loss, but it ended on a sweeter note after Friday’s rally. Now, we're taking a closer look at inflation and the market. 
Via InvestorPlace
Contraceptives Market New Innovations Trends, Research, Global Share and Growth Factor
Contraceptives Market New Innovations Trends, Research, Global Share and Growth Factor The use of advanced contraceptive methods and emergency contraceptives methods, especially for teenagers, and... 
Via iCrowdNewswire
Topics Economy
Exposures COVID-19 Supply Chain
Asia-Pacific Anti-Inflammatory Therapeutics Market Qualitative Insights on Application & Outlook by Share, Future Growth
Asia-Pacific Anti-Inflammatory Therapeutics Market Qualitative Insights on Application & Outlook by Share, Future Growth Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR... 
Via iCrowdNewswire
Topics Intellectual Property
Exposures Intellectual Property
Insider Buying Remains Elevated For A Second Week $SBUX $UBER $RILY
In an unusually volatile week, we saw significant market weakness earlier in the week probably driven by forced selling and a relief rally in the end. Insiders once again stepped up their purchases to... 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 16
CNBC Volkswagen CEO Shares Ambitious EV Ambitions For US Market 
Via Benzinga
Pfizer/BioNTech COVID-19 Vaccine's European Delivery Takes Backseat To Help Booster Campaign
 
Via Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
Johnson & Johnson Stock: A Rare Bright Spot in the Market
JNJ stock is up on the year thanks in part to its steadily rising dividend, which investors covet during the current market volatility. 
Via InvestorPlace
7 Profitable Places to Hide Your Money During a Bear Market
With an imminent bear market on the horizon, investors are searching for alternative investment paths for diversification. 
Via InvestorPlace
Biden Says US Ready To Share COVID-19 Vaccine Related Technology
 
Via Benzinga
White House Says Currently No Plans To Share COVID-19 Shots With North Korea Battling Outbreak
The Biden administration says it currently has no plans to share COVID-19 vaccines with North Korea, Reuters reported citing White House press secretary Jen Psaki. However, it supported providing aid... 
Via Benzinga
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
The race is on in eczema treatment as the biggest name faces new rivals. 
Via Investor's Business Daily
Stock Market Tries To Bounce From Fresh 2022 Lows; Tesla CEO Elon Musk Puts Twitter Deal 'On Hold': Weekly Review
Elon Musk put his Twitter deal "on hold" but says he's "still committed" to it. 
Via Investor's Business Daily
7 Cheap Stocks to Buy Now for a Rich Retirement
It's never too early to start retirement planning, and these cheap stocks to buy will give your portfolio a good start. 
Via InvestorPlace
COVID-19 Symptoms Rebound After Pfizer's COVID-19 Therapy, What Could Be The Reason?
Some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement after Pfizer Inc's (NYSE: PFE) COVID-19 oral antiviral treatment Paxlovid. 
Via Benzinga
INO Stock Plunges 25% as Inovio Pharmaceuticals Swaps Vaccine Focus
Inovio Pharmaceuticals has halted its Covid-19 progress to focus on a booster. Here's why this news is unlikely to boost INO stock. 
Via InvestorPlace
103 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Market Selloff
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.